42200-33-9

• 常用中文名：苯甲丁氮酮
• 常用英文名：Nadolol
• CAS号：42200-33-9
• 分子式：C₁₇H₂₇NO₄
• 分子量：309.40100
• 相关类别： 原料药 循环系统用药 抗心律失常药
• 发布时间：2018-04-30 08:00:00
• 更新时间：2026-07-07 19:13:02
• Nadolol (SQ-11725) 是一种非选择性的具有口服活性的 β-肾上腺素受体 (β-adrenergic receptors) 阻滞剂,也是有机阴离子转运多肽 1A2 (OATP1A2) 的一种底物。Nadolol 可用于高血压,心绞痛和血管性头痛的研究。

名称

• 中文名: 苯甲丁氮酮
• 英文名: (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol
• 中文别名: 康加尔多; 纳多洛尔(NADOLOL) 标准品; 康格多; 纳多洛尔中间体; 萘羟心胺; 乙腈中纳多洛尔溶液标准物质; 洛多洛尔; 1,2,3,4-四氢-5-[2-羟基-3-(叔丁氨)丙氧基]-2,3-萘二醇; 纳多洛尔溶液, 100PPM; 纳多洛尔相关杂质; 纳多洛尔; 康格尔 标准品; 甲醇中纳多洛尔溶液标准物质; 羟氢萘心安; 2,3-顺式-1,2,3,4-四氢-5-[2-羟基-3-(叔丁氨)丙氧基]-2,3-萘二醇; 萘肟洛尔; 萘多洛尔; 萘丁乐; 纳多洛尔 标准品; 康格尔; 氢萘心安
• 英文别名: 1-(tert-Butylamino)-3-((5,6,7,8-tetrahydro-cis-6,7-dihydroxy-1-naphthyl)oxy)-2-propanol; NADOLOL //BP; corzide; 2,3-diol; (2R,3R)-5-[3-(tert-butylaMino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol; 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- (9CI); (2R,3S)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; 1-tert.-butylamino-3-(1,2,3,4-tetrahydro-2,3-dihydroxy-5-napthyloxy)-2-propanol; 1-(tert-bytylamino)-3-((5,6,7,8-tetrahydro-cis-6,7-dihydroxy-1-naphthyl)oxy)-2; 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxyl)-1,2,3,4-tetrahydro-2,3-naph; NADOLOL; 5-[3-[(1,1-DiMethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro; cis-5-[(2RS)-3-[(1,1-Dimethylethyl)amino]-2- hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol; 5-[3-[(1,1-DiMethylethyl-d9)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro; 3s)-5-(3-(tert-butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-(2; nadolol; 5-(3-(tert-butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol - [AC80382]; Corgd; 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,-naphthalenediol; 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro; Nadic; Nadolol 1.0 mg/ml in Methanol; hthalenediol; Nadolol-d5; Nadololum [INN-Latin]; Nadolol in methanol; [14C]-Nadolol; alenediol; 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro-, cis; 5-[3-(tert-butylamino)-2-oxopropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol; 2,3-cis-1,2,3,4-tetrahydro-5-(2-hydroxy-3-(tert-butylamino)propoxy)-2,3-naphth; 5-(3-(tert-Butylamino); Corgard; thalenediol; 5-[3-[(1,1-dimethylethyl)-amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro-2,3-cis-naphthalenediol; NadololQ: What is Nadolol Q: What is the CAS Number of Nadolol Q: What is the storage condition of Nadolol Q: What e the applications of Nadolol; 5-[3-(tert-Butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydro-2,3-naphthalenediol; 2,3-cis-1,2,3,4-tetrahydro-5-((2-hydroxy-3-tert-butylamino)propoxy)-2,3-naph; Begen; NADOLOL-D9; Nadolol CRS; Nadolol 10 μg/ml Acetonitrile; Solgol; 2-hydroxypropoxy); Nadololum; 1,2,3,4-tetrahydronaphthalene-2,3-diol; Corgaretic; pressure,Adrenergic Rector,Nadolol,pectoris,substrate,SQ-11725,high,β-adrenergic,OATP1A2,Beta Rector,inhibit,vascul,blood,headaches,SQ 11725,Inhibitor,angina; 2,3-cis-1,2,3,4-Tetrahydro-5-((2-hydroxy-3-tert-butylamino)propoxy)-2,3-naphthalenediol; 1-(tert-butylamino)-3-((5,6,7,8-tetrahydro-cis-6,7-dihydroxy-1-naphthyl)oxy); 5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-2,3-naphthalenediol; Anabet; 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-2,3-nap

物化性质

• 密度: 1.189g/cm3
• 沸点: 526.4ºC at 760mmHg
• 熔点: 125-130ºC
• 分子式: C₁₇H₂₇NO₄
• 分子量: 309.40100
• 闪点: 272.2ºC
• 精确质量: 309.19400
• PSA: 81.95000
• LogP: 1.02570
• 外观性状: 白色固体
• 折射率: 1.573
• 储存条件: Refrigerator
• 水溶解性: Slightly soluble in water, freely soluble in ethanol (96 per cent), practically insoluble in acetone.

生物活性

• 描述: Nadolol (SQ-11725) 是一种非选择性的具有口服活性的 β-肾上腺素受体 (β-adrenergic receptors) 阻滞剂,也是有机阴离子转运多肽 1A2 (OATP1A2) 的一种底物。Nadolol 可用于高血压,心绞痛和血管性头痛的研究。
• 相关类别:
  研究领域 >> 心血管疾病
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 肾上腺素能受体
• 体外研究: 在人胚肾293细胞中,(-)-表没食子儿茶素没食子酸酯(EGCG)竞争性地抑制OATP1A2介导的纳多洛尔摄取,Ki值为19.4μM。相对于纳多洛尔,OATP1A2的Km为84μM[2]。
• 体内研究: 在携带B16F10肿瘤细胞的1只雄性小鼠中,通过给予纳多洛尔(20mg/kg)阻断神经内分泌反应,导致暴露于急性社会压力的受试者的肺转移灶越来越小[3]。
• 参考文献:

  [1]. Johannes C von Alvensleben, et al. Nadolol for Treatment of Supraventricular Tachycardia in Infants and Young Children. Pediatr Cardiol. 2017 Mar;38(3):525-530.

  [2]. Osamu Abe, et al. Role of (-)-Epigallocatechin Gallate in the Pharmacokinetic Interaction Between Nadolol and Green Tea in Healthy Volunteers. Eur J Clin Pharmacol. 2018 Jun;74(6):775-783.

  [3]. O Vegas, et al. Effects of Antalarmin and Nadolol on the Relationship Between Social Stress and Pulmonary Metastasis Development in Male OF1 Mice. Behav Brain Res. 2009 Dec 14;205(1):200-6.

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : QJ4870000 CHEMICAL NAME : 2,3-Naphthalenediol, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2 ,3,4-tetrahydro- CAS REGISTRY NUMBER : 42200-33-9 LAST UPDATED : 199506 DATA ITEMS CITED : 19 MOLECULAR FORMULA : C17-H27-N-O4 MOLECULAR WEIGHT : 309.45 WISWESSER LINE NOTATION : L66&TJ BO1YQ1MX1&1&1 HQ IQ HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 571 ug/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - visual field changes REFERENCE : AIMEAS Annals of Internal Medicine. (American College of Physicians, 4200 Pine St., Philadelphia, PA 19104) V.1- 1927- Volume(issue)/page/year: 97,454,1982 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 64 mg/kg/4W-I TOXIC EFFECTS : Gastrointestinal - changes in structure or function of endocrine pancreas REFERENCE : BJCPAT British Journal of Clinical Practice. (Medical News Group, 1 Bedford St., London WC2E 9HD, UK) V.10(10)- 1956- Volume(issue)/page/year: 43,74,1989 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 5300 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : 43NDAD "Pharmacology of Antihypertensive Drugs," Scriabine, A., ed., New York, Raven Press, 1980 Volume(issue)/page/year: -,295,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 322 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 16,1461,1985 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >1 gm/kg TOXIC EFFECTS : Skin and Appendages - dermatitis, other (after systemic exposure) REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 9,527,1981 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 59200 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 16,1461,1985 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 3800 mg/kg TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold Behavioral - antipsychotic Lungs, Thorax, or Respiration - cyanosis REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 9,527,1981 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 270 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : 43NDAD "Pharmacology of Antihypertensive Drugs," Scriabine, A., ed., New York, Raven Press, 1980 Volume(issue)/page/year: -,295,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >1 gm/kg TOXIC EFFECTS : Skin and Appendages - dermatitis, other (after systemic exposure) REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 9,527,1981 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 47100 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 16,1461,1985 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : >500 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,767,1990 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 182 gm/kg/26W-I TOXIC EFFECTS : Kidney, Ureter, Bladder - urine volume increased Kidney, Ureter, Bladder - other changes in urine composition Nutritional and Gross Metabolic - weight loss or decreased weight gain REFERENCE : FAATDF Fundamental and Applied Toxicology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1981- Volume(issue)/page/year: 4,360,1984 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 72 gm/kg/30D-I TOXIC EFFECTS : Behavioral - food intake (animal) Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 9,527,1981 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 29120 mg/kg/26W-I TOXIC EFFECTS : Vascular - BP lowering not characterized in autonomic section REFERENCE : FAATDF Fundamental and Applied Toxicology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1981- Volume(issue)/page/year: 4,360,1984 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 550 mg/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - behavioral REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 11,5119,1983 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1650 mg/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 11,5119,1983 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 42 gm/kg SEX/DURATION : male 9 week(s) pre-mating female 14 day(s) pre-mating - 7 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Effects on Newborn - sex ratio REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 11,5119,1983 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 13 gm/kg SEX/DURATION : male 9 week(s) pre-mating female 14 day(s) pre-mating - 7 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 11,5119,1983 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1300 mg/kg SEX/DURATION : female 6-18 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) REFERENCE : TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 44,379,1978

安全

• 个人防护装备: Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
• 危险品运输编码: NONH for all modes of transport
• WGK德国: 2
• RTECS号: QJ4870000
• 海关编码: 2922509090

海关

海关编码	2922509090
中文概述	2922509090. 其他氨基醇酚、氨基酸酚及其他含氧基氨基化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件：AB. 最惠国关税:6.5%. 普通关税:30.0%
申报要素	品名, 成分含量, 用途, 乙醇胺及其盐应报明色度, 乙醇胺及其盐应报明包装
监管条件	A.入境货物通关单 B.出境货物通关单
检验检疫	R.进口食品卫生监督检验 S.出口食品卫生监督检验
Summary	2922509090. other amino-alcohol-phenols, amino-acid-phenols and other amino-compounds with oxygen function. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%